Side Effects of Exelon Patch
The Exelon (rivastigmine) transdermal patch causes primarily application site skin reactions (redness, itching, irritation, swelling) in approximately 60% of patients, along with gastrointestinal effects (nausea, vomiting, diarrhea) that are significantly less frequent than oral formulations but still occur in 7% and 6% of patients respectively. 1
Most Common Side Effects
Application Site Reactions (Most Frequent)
- Skin reactions at patch site: redness, itching, irritation, and swelling occur in approximately 60% of patients 2
- These are typically mild and can be managed with proper site rotation and good skin care 3, 4
- Most reactions are irritant contact dermatitis (confined to patch borders) rather than true allergic reactions 4
- Application site reactions are the leading cause of discontinuation in patients who stop the patch 2
Gastrointestinal Effects (Markedly Reduced vs. Oral)
The patch formulation substantially reduces GI side effects compared to oral rivastigmine:
- Nausea: 7% with 9.5 mg/24h patch vs. 23% with oral capsules 1
- Vomiting: 6% with 9.5 mg/24h patch vs. 17% with oral capsules 1
- Diarrhea: 6% with patch vs. higher rates with oral 1
- Severe vomiting: 0% with 9.5 mg/24h patch vs. 1% with oral 1
Other Common Side Effects
- Loss of appetite
- Anxiety and difficulty sleeping
- Dizziness and headache
- Stomach discomfort after meals
- Fatigue and weakness
- Weight loss (8% had ≥7% weight loss with 9.5 mg/24h patch) 1
Serious Side Effects (Uncommon but Important)
Remove the patch immediately and contact your physician if you experience:
- Severe confusion or hallucinations
- Fainting or loss of consciousness
- Irregular, fast, or slow heartbeat
- Signs of stroke (loss of coordination, difficulty speaking/breathing)
- Gastric ulcer or gastrointestinal bleeding (blood in stools or vomit)
- Depression 1
Dose-Related Considerations
Critical caveat: The higher dose patch (17.4 mg/24h) shows substantially increased side effects:
- Nausea: 21% (vs. 7% with 9.5 mg/24h)
- Vomiting: 19% (vs. 6% with 9.5 mg/24h)
- Weight loss ≥7%: 12% (vs. 8% with 9.5 mg/24h) 1
Approximately 70% of adverse events occur before reaching maintenance dose, with most application site discontinuations happening when increasing to 9 mg 2.
Discontinuation Rates
- Overall discontinuation due to adverse events: 14.6% with patch vs. 19.3% with oral capsules 5
- 37.8% of patients discontinued the patch in real-world use, with 62.7% of these due to application site reactions 2
- Discontinuation for vomiting: 0% with 9.5 mg/24h patch vs. 2% with oral 1
Overdose Symptoms
If multiple patches are accidentally applied, symptoms may include:
- Severe nausea, vomiting, diarrhea
- High blood pressure
- Hallucinations
- Slow heartbeat and fainting 1
Remove all patches immediately and seek medical attention 1.
Comparative Safety Profile
The transdermal patch demonstrates superior tolerability compared to oral rivastigmine, with an 8-fold reduction in nausea (3.8% vs. 32.9%) and 6-fold reduction in vomiting (4.2% vs. 24.1%) when switching from oral to patch 5. This improved GI tolerability comes at the cost of application site reactions, which are generally manageable with proper technique 3, 4.